Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Rex Fang & Innovation Equity Premium Income ETF (FEPI) vs GeneDx Holdings Corp (WGS) Price & Performance

Rex Fang & Innovation Equity Premium Income ETFTrade
GeneDx Holdings CorpTrade

Price performance (Past 24H)

Key statistics

Rex Fang & Innovation Equity Premium Income ETF vs GeneDx Holdings Corp — how do they compare? Rex Fang & Innovation Equity Premium Income ETF trades at $41.6, while GeneDx Holdings Corp trades at $63.83 (market cap $1.96B). Which is the better fit depends on your goals.

FEPIWGS
Sector
Income / Options OverlayTechnology
52-Week High
$49.54$167.51
52-Week Low
$38.13$34.51
Market Cap
$1.96B
Enterprise Value
$1.96B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Rex Fang & Innovation Equity Premium Income ETF

FEPI trades at $41.76, down 1.6% today, with a bearish technical signal from moving averages. The ETF generates high income through weekly covered call distributions, recently transitioning to weekly payouts. Recent dividends show consistent payments around $0.20-$0.22 per share, with one larger $0.90 distribution in April 2026. The concentrated portfolio of AI and mega-cap tech names provides QQQ-like exposure but with capped upside from call writing.

The outlook remains cautious due to NAV erosion risks from the covered call strategy limiting participation in rallies. While the 25% yield attracts income seekers, total returns have lagged broader tech indices. Key risks include high portfolio concentration and market volatility impacting premium income generation. Analyst views are mixed, balancing high yield against structural limitations.

GeneDx Holdings Corp

GeneDx Holdings Corp. (WGS) trades at $65.785, up 5.37% today, but faces a bearish technical signal with the stock near resistance at $65. The company shows mixed fundamentals with strong revenue growth to $427.54M in 2025 but a net loss of -$21.02M, while analyst consensus remains bullish with a $75.40 price target. Recent news highlights multiple class-action lawsuits alleging securities fraud tied to a 49% stock decline and acquisition underperformance, creating significant investor uncertainty.

The outlook is highly conflicted: strong analyst buy ratings and recent earnings beats contrast with deepening losses, negative cash flow projections for 2026, and legal overhangs. Key risks include litigation outcomes, profitability challenges, and execution missteps, but the stock offers potential upside if the company can stabilize margins and resolve legal issues amid high institutional skepticism.

Returns comparison

Trailing returns across standard periods

About Rex Fang & Innovation Equity Premium Income ETF

FEPI provides exposure to top innovation stocks while generating monthly income. It uses a covered call strategy on high-volatility tech stocks to capture option premiums for investors.

Read more on FEPI

About GeneDx Holdings Corp

GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.

Read more on WGS